June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
shRNA Gene-silencing Therapy for Congenital Stromal Corneal Dystrophy
Author Affiliations & Notes
  • Rajiv Mohan
    Mason Eye Institute, University of Missouri-Columbia, Columbia, MO
  • Ajay Sharma
    Mason Eye Institute, University of Missouri-Columbia, Columbia, MO
  • Jason Rodier
    Mason Eye Institute, University of Missouri-Columbia, Columbia, MO
  • Ashish Tandon
    Mason Eye Institute, University of Missouri-Columbia, Columbia, MO
  • David Birk
    Mason Eye Institute, University of Missouri-Columbia, Columbia, MO
  • Footnotes
    Commercial Relationships Rajiv Mohan, None; Ajay Sharma, None; Jason Rodier, None; Ashish Tandon, None; David Birk, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 4742. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Rajiv Mohan, Ajay Sharma, Jason Rodier, Ashish Tandon, David Birk; shRNA Gene-silencing Therapy for Congenital Stromal Corneal Dystrophy. Invest. Ophthalmol. Vis. Sci. 2013;54(15):4742.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Recently, a mouse model that recapitulates autosomal human congenital stromal corneal dystrophy (CSCD) phenotype and pathophysiology using mutant decorin (952delT comparable to human 967delT) has been developed. Penetrating keratoplasty is used to treat CSCD as no therapeutic option is available currently. We hypothesize that targeted AAV-short-hairpin RNA gene-silencing therapy targeting mutant decorin mRNA degradation can rescue CSCD pathology in mouse model in vivo. This study validated the hypothesis using an in vitro model.

Methods: Human corneal fibroblasts (HCF) and HEK293 cell (293) line were used. The human and mouse decorin-specific and scrambled shRNA oligos were designed and cloned into mammalian expression vector pENTRT6.1 that drives gene expression under control of Pol III promoter. Lipofectamine LTX solution was used for transfections and G418 antibiotic was used for stable clone selection. Gene transfer levels were confirmed with real-time PCR and ELISA. The knockdown efficiency of 10 sets of shRNA-dcn was characterized using quantitative real-time PCR, ELISA, and western blotting.

Results: The generated HCF-dcn and 293-dcn clones overexpressing decorin were identified. Selected HCF-dcn and 293-dcn clones showed remarkably high levels of decorin mRNA and protein in qPCR and ELISA analyses. The efficacy of 5 sets of mouse shRNA-dcn to silence decorin mRNA and protein levels was remarkably high in 293-dcn cultures (74-91%). The decorin-silencing was greatest with set-1 and set-3 (>91%; p<0.001). Gene silencing efficiencies of human dcn-shRNA was analyzed in HCF-dcn. The tested 3 shRNA-dcn sets specific for human decorin mRNA degradation demonstrated 73-83% decorin silencing in HCF-dcn (p <0.01). The scrambled shRNA plasmid transfection (negative control) showed no decrease in decorin in 293-dcn and HCF-dcn.

Conclusions: shRNA-based targeted gene-silencing therapy has potential to rescue CSCD phenotype. In vivo studies are warranted.

Keywords: 484 cornea: stroma and keratocytes • 538 gene transfer/gene therapy • 480 cornea: basic science  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×